New Harvard study shows cervical cancer vaccine Gardasil worth the cost

Washington, D.C.

According to a new study released by Harvard researchers, the cervical cancer vaccine Gardasil is well worth the cost to protect girls against the virus.
Harvard researchers took part in a study which looked at just how cost-effective the cervical cancer vaccine Gardasil actually was.
What they found was that the most cost-effective way to fight the virus using Gardasil would be to vaccine all 12-year old girls.
Beyond that, you would also have to immunize all women under the age of 21, and revise screening guidelines.
Their study on how cost-effective the cervical cancer vaccine is has been published in the August 21 issue of the New England Journal of Medicine.
The cervical cancer vaccine Gardasil helps protect against two strains of HPV, which are responsible for 70% of cervical cancer cases around the world.
Gardasil was approved back in 2006 and was recommended by the CDC for girls who are ages 11 or 12-years old.
The Harvard researchers also found that the cervical cancer vaccine may not be as cost-effective for older women, over the age of 21.

 Subscribe to Cervical Cancer News Information Links